Evidence map›Paper›PMID 31819304›Full record

Trial reportMedical archives (Sarajevo, Bosnia and Herzegovina)2019

Usage of Probiotics and its Clinical Significance at Surgically Treated Patients Sufferig from Colorectal Carcinoma.

Salem Bajramagic, Edin Hodzic, Adi Mulabdic, Sandin Holjan, Sajra Vincevic Smajlovic, Ajdin Rovcanin

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Medical archives (Sarajevo, Bosnia and Herzegovina), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 9 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 9 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Salem BajramagicClinic for General and Abdominal Surgery, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Edin HodzicClinic for General and Abdominal Surgery, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Adi MulabdicClinic for General and Abdominal Surgery, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Sandin HoljanClinic for General and Abdominal Surgery, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Sajra Vincevic SmajlovicDepartment of Microbiology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Ajdin RovcaninClinic for General and Abdominal Surgery, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Clinical Center University of Sarajevo · BAUniversity of Sarajevo · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionColorectal Cancer (CRC) is the third most common malignant disease and the fourth most common cause of death associated with malignancy. Adenocarcinomas account for 95% of all cases of colon cancer. Treatment usually includes a surgical resection which is preceded or followed by chemotherapy and radiotherapy depending on the stage. There is constant interest in the microbiological ecosystem of the intestine, which is considered to be crucial for the onset and progression of the disease as well as the development of postoperative complications. Iatrogenic factors associated with the treatment of CRC may result in pronounced expression of virulence of the bacterial intestinal flora and fulminant inflammatory response of the host which ultimately leads to adverse treatment results. The modulation of intestinal microflora by probiotics seems to be an effective method of reducing complications in surgical patients. The question is whether ordering probiotics can lead to more favourable treatment outcomes for our patients who are operated due to colorectal adenocarcinoma, and whether this should become common practice.

aimTo demonstrate the clinical significance of probiotic administration in patients treated for colorectal adenocarcinoma and the results compared with relevant studies. PATIENTS AND

methodsIn a randomized controlled prospective study conducted at the Clinic of General and Abdominal Surgery of the UCCS in the period of 01 January 2017 until 31 December 2017, there were a total of 78 patients with colorectal adenocarcinoma. Patients were divided into two groups: a group treated with oral probiotics (n = 39) according to the 2x1 scheme starting from the third postoperative day lasting for the next thirty days, followed by 1x1 lasting for two weeks in each subsequent month to one year, and the control group (n = 39) which was not routinely treated with probiotics.

resultsA statistically significant difference in the benefit of using probiotics was found during postoperative hospitalization and the occurrence of fatal outcome in the first six months. All complications were more present in the group of patients untreated with probiotic, with statistical significance shown only in the case of ileus. Probiotic has a statistically significant reduction in postoperative complications in the localization of tumours on the rectum -33.3% and the ascending colon -16.7%.

conclusionThere is a significant benefit of administering probiotics in surgically treated patients for colorectal adenocarcinoma.

Indexed as

ColectomyAbdominal AbscessAdenocarcinomaAnastomotic LeakBifidobacteriumColon, AscendingColorectal NeoplasmsHumansIleusLactobacillusNeoplasm StagingPostoperative CarePostoperative ComplicationsProbioticsRectal NeoplasmsStreptococcus thermophiluscolon surgerycolorectal cancerprobioticssurgical complications

Identifiers

PMID31819304
PMCPMC6885229
OpenAlexW2983022360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.